Robeco Institutional Asset Management B.V. Has $833,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Robeco Institutional Asset Management B.V. lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 20.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,228 shares of the medical research company’s stock after selling 1,107 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Charles River Laboratories International were worth $833,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CRL. Texas Permanent School Fund Corp increased its position in shares of Charles River Laboratories International by 3.0% during the 1st quarter. Texas Permanent School Fund Corp now owns 10,602 shares of the medical research company’s stock worth $2,873,000 after purchasing an additional 307 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Charles River Laboratories International by 2.1% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 9,631 shares of the medical research company’s stock worth $2,610,000 after purchasing an additional 200 shares in the last quarter. Empowered Funds LLC increased its position in Charles River Laboratories International by 10.0% in the 1st quarter. Empowered Funds LLC now owns 3,344 shares of the medical research company’s stock valued at $906,000 after acquiring an additional 304 shares in the last quarter. SG Americas Securities LLC increased its position in Charles River Laboratories International by 23.4% in the 1st quarter. SG Americas Securities LLC now owns 16,362 shares of the medical research company’s stock valued at $4,433,000 after acquiring an additional 3,108 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Charles River Laboratories International in the 1st quarter valued at about $473,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 2.4 %

Charles River Laboratories International stock opened at $215.39 on Monday. The company’s 50 day simple moving average is $193.91 and its 200 day simple moving average is $208.05. Charles River Laboratories International, Inc. has a fifty-two week low of $166.87 and a fifty-two week high of $275.00. The firm has a market capitalization of $11.01 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 7.22 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.21.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the previous year, the firm posted $2.72 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a share buyback plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Analysts Set New Price Targets

CRL has been the subject of several research reports. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price objective for the company. Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. TD Cowen lowered their price objective on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research report on Monday, August 12th. Bank of America cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $250.00 to $215.00 in a research report on Wednesday, October 2nd. Finally, CLSA raised shares of Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 target price on the stock in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average target price of $215.69.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).